-
2025 FACO | Professors Tetsuya Mitsudomi & Yun Gyoo Lee: Strengthening China–Japan–Korea Collaboration to Address Shared Challenges in Lung Cancer Care
China, Japan, and South Korea have long ranked among the countries with the highest incidence of lung cancer worldwide. With a heavy disease burden, urgent unmet medical needs, and remarkably similar disease characteristics, strengthening trilateral collaboration among these East Asian nations is critical to advancing clinical oncology and addressing shared challenges in lung cancer management.
-
Professors Michael R. Bishop and Edmund K. Waller Visit Peking University Institute of Hematology:Sino–U.S. Experts Discuss the Future of Cell Therapy
On November 2, 2025, world-renowned hematology experts Professor Michael R. Bishop, Director of the Cell Therapy Center at the University of Chicago, and Professor Edmund K. Waller, the Rein Saral Distinguished Chair at Emory University, visited the Peking University Institute of Hematology for an academic exchange.
-
Prof. Kun Wang: A 72-Hour Pegfilgrastim Dosing Strategy Significantly Reduces Bone Pain and Optimizes Supportive Care in Breast Cancer
Editor’s Note At the ESMO 2025 Congress, Prof. Kun Wang from Guangdong Provincial People’s Hospital delivered an oral presentation reporting results from a prospective phase III trial exploring the relationship…
-
ESMO China Voice | Prof. Guiying Xu: High Concordance of PIK3CA Mutations Between Primary and Metastatic Lesions in HR+/HER2– Breast Cancer
Editor’s Note The European Society for Medical Oncology (ESMO) 2025 Annual Congress, held in Berlin, Germany from October 17–21, gathered leading global experts to share groundbreaking advances in cancer diagnosis…
-
ESMO China Voice | Prof. Min Yan: First Data from the JS105 Study Announced — Promising Potential in PIK3CA-Mutant Populations
Editor’s Note: At the 2025 ESMO Annual Congress in Berlin, multiple innovative therapies attracted wide attention. Among them, the selective PI3K-α inhibitor JS105 released the first results from two Phase…
-
ESMO China Voice | Prof. Jiayu Wang: MAIC Analysis Highlights the Potential of Bireociclib as a Second-Line Therapy for HR+/HER2– Advanced Breast Cancer, Offering a New Treatment Option for Patients
In the second-line treatment of hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer, CDK4/6 inhibitors combined with fulvestrant have become the standard of care. However, variations in efficacy and safety profiles among different inhibitors remain an important clinical consideration.
-
Prof. Man Li’s Team Reveals CDK12–ERBB2 Co-Amplification Mechanism and Explores a Novel “Metabolism–Repair–Resistance” Pathway
The 2025 European Society for Medical Oncology (ESMO) Annual Congress, held in Berlin, Germany from October 17 to 21, brought together global experts to present cutting-edge advances in cancer research — from basic science to translational breakthroughs and clinical innovation.
-
ESMO Hot Topic | Professor Zhao Yanxia: PATINA Trial PRO Data Confirm Palbociclib Combination Extends PFS Without Compromising Quality of Life
The PATINA (AFT-38) trial is a randomized, open-label, phase III study designed to evaluate the efficacy and safety of palbociclib + HER2-targeted therapy + endocrine therapy versus HER2-targeted therapy + endocrine therapy alone in patients with HR+/HER2+ metastatic breast cancer following induction therapy. Previous data from PATINA demonstrated that the addition of palbociclib significantly prolonged…
Connecting Medical Expertise through Media